Analysis of urinary kallikrein-related peptidase 13 for monitoring bladder cancer.


Journal

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
ISSN: 1366-5804
Titre abrégé: Biomarkers
Pays: England
ID NLM: 9606000

Informations de publication

Date de publication:
Dec 2021
Historique:
pubmed: 28 10 2021
medline: 8 3 2022
entrez: 27 10 2021
Statut: ppublish

Résumé

Bladder cancer (BC) is one of the 10 most common types of cancer worldwide, with approximately 550,000 new cases each year. Early detection and appropriate diagnosis are important factors in successful treatment of the disease. We used specific fluorogenic substrate for the quantitative determination of urine kallikrein 13 (KLK13) activity in healthy ( Urine samples from patients with G2 and G3 grade BC contained proteolytically active KLK13, as confirmed by kinetic analysis and immunochemical detection. KLK13 was not detected in the urine of patients with G1 grade BC. Previous clinical study reveals the KLK13 significance for BC prognosis as increased Using specific chromogenic/fluorogenic peptides could be useful for the non-invasive disease monitoring of BC progress.

Sections du résumé

BACKGROUND BACKGROUND
Bladder cancer (BC) is one of the 10 most common types of cancer worldwide, with approximately 550,000 new cases each year. Early detection and appropriate diagnosis are important factors in successful treatment of the disease.
MATERIAL AND METHODS METHODS
We used specific fluorogenic substrate for the quantitative determination of urine kallikrein 13 (KLK13) activity in healthy (
RESULTS RESULTS
Urine samples from patients with G2 and G3 grade BC contained proteolytically active KLK13, as confirmed by kinetic analysis and immunochemical detection. KLK13 was not detected in the urine of patients with G1 grade BC.
DISCUSSION CONCLUSIONS
Previous clinical study reveals the KLK13 significance for BC prognosis as increased
CONCLUSIONS CONCLUSIONS
Using specific chromogenic/fluorogenic peptides could be useful for the non-invasive disease monitoring of BC progress.

Identifiants

pubmed: 34704886
doi: 10.1080/1354750X.2021.1999502
doi:

Substances chimiques

Biomarkers, Tumor 0
KLK13 protein, human EC 3.4.21.-
Kallikreins EC 3.4.21.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

770-779

Auteurs

Natalia Gruba (N)

Department of Environmental Technology, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland.

Patrycja Rachubik (P)

Laboratory of Molecular and Cellular Nephrology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Gdańsk, Poland.

Agnieszka Piwkowska (A)

Laboratory of Molecular and Cellular Nephrology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Gdańsk, Poland.
Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland.

Adam Lesner (A)

Department of Environmental Technology, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH